Comparing of Chimerix Inc. (CMRX) and Arbutus Biopharma Corporation (NASDAQ:ABUS)

This is therefore a comparing of the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation in Chimerix Inc. (NASDAQ:CMRX) and Arbutus Biopharma Corporation (NASDAQ:ABUS). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chimerix Inc. 8.78M 20.41 67.34M -1.43 0.00
Arbutus Biopharma Corporation 5.19M 16.00 73.35M -1.32 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Chimerix Inc. and Arbutus Biopharma Corporation.


Table 2 demonstrates the return on equity, net margins and return on assets of Chimerix Inc. and Arbutus Biopharma Corporation.

Net Margins Return on Equity Return on Assets
Chimerix Inc. -766.97% -37.3% -35.1%
Arbutus Biopharma Corporation -1,413.29% -87.5% -30.6%

Volatility and Risk

Chimerix Inc. has a 1.43 beta, while its volatility is 43.00%, thus making it more volatile than Standard and Poor’s 500. In other hand, Arbutus Biopharma Corporation has beta of 1.67 which is 67.00% more volatile than Standard and Poor’s 500.


Chimerix Inc.’s Current Ratio is 13.6 while its Quick Ratio is 13.6. On the competitive side is, Arbutus Biopharma Corporation which has a 12.7 Current Ratio and a 12.7 Quick Ratio. Chimerix Inc. is better positioned to pay off short and long-term obligations compared to Arbutus Biopharma Corporation.

Analyst Ratings

Ratings and Recommendations for Chimerix Inc. and Arbutus Biopharma Corporation can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Chimerix Inc. 0 3 1 2.25
Arbutus Biopharma Corporation 0 0 0 0.00

The downside potential is -0.28% for Chimerix Inc. with consensus target price of $3.5.

Institutional and Insider Ownership

The shares of both Chimerix Inc. and Arbutus Biopharma Corporation are owned by institutional investors at 80.1% and 44.6% respectively. Insiders held roughly 1.3% of Chimerix Inc.’s shares. Comparatively, insiders own roughly 3% of Arbutus Biopharma Corporation’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Chimerix Inc. 37.83% 39.39% 73.58% 10.84% -20.69% 43.19%
Arbutus Biopharma Corporation -0.42% -36.02% -38.82% -48.82% -64.21% -37.86%

For the past year Chimerix Inc. had bullish trend while Arbutus Biopharma Corporation had bearish trend.


On 9 of the 11 factors Chimerix Inc. beats Arbutus Biopharma Corporation.

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The companyÂ’s lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat HIV and hepatitis B virus infection. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The companyÂ’s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also comprise ARB-1740, a pan-genotypic second-generation siRNA therapeutic in Phase II multi-dose study in Hepatitis B e antigen-chronic HBV patients; and AB-423, a core protein/capsid assembly inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates, including oral surface antigen inhibitors, cccDNA targeting agents, and immunomodulators. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and DCR-PH1 for the treatment of primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.